COMMUNIQUÉS West-GlobeNewswire

Dyadic to Attend Industry Events in April

27/03/2024 - 13:30

JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the [...]

Wave Life Sciences to Present at Upcoming Investor Conferences

27/03/2024 - 13:30

CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

27/03/2024 - 13:30

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

27/03/2024 - 13:30

LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE [...]

CorMedix Inc. to Present at the Needham Annual Healthcare Conference

27/03/2024 - 13:30

BERKELEY HEIGHTS, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of [...]

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

27/03/2024 - 13:30

SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]

Markham Fertility Centre and humm Canada partner to make fertility treatments more accessible

27/03/2024 - 13:12

MARKHAM, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- Markham Fertility Centre (MFC) and humm Canada proudly come together to announce better financing options for patients seeking fertility treatments. Time, cost, and [...]

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

27/03/2024 - 13:07

SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the [...]

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

27/03/2024 - 13:05

- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger [...]

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

27/03/2024 - 13:03

CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing [...]

Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

27/03/2024 - 13:02

The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc [...]

R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report

27/03/2024 - 13:00

Report highlights R1’s commitment to corporate responsibility and sustainability across the company’s global footprint MURRAY, Utah, March 27, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading [...]

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

27/03/2024 - 13:00

- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1 portion of the Phase 1/2a [...]

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

27/03/2024 - 13:00

–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis [...]

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

27/03/2024 - 13:00

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress [...]

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

27/03/2024 - 13:00

Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a [...]

Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium

27/03/2024 - 13:00

New Provectus Spinout Company Would Commercialize Combination Therapy of University’s Light Source Medical Device and Provectus’s Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March 27, 2024 (GLOBE NEWSWIRE [...]

One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors

27/03/2024 - 13:00

Dr. Scott Braunstein, Chairman and CEO of Marinus Pharma and Operating Partner of Aisling Capital; and Dr. Vincent Miller, global expert in cancer, and clinical trial design and interpretation join ahead of One [...]

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

27/03/2024 - 13:00

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]